Company News

Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors

PRNewswire: March 23, 2017 – CAMBRIDGE, MA, U.S.A. – Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the enrollment of its first patient in a phase 1 study of MM-310 in solid tumors. MM-310 is an antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane and targets the EphA2 receptor, a protein which surveys suggest is overexpressed in 50–100% of many major tumor types, including prostate, ovarian, bladder, gastric, pancreatic, and lung cancers.

Read More

Effective One-Shot Vaccination of Newborns Moves Closer to Reality

PRNewswire: March 23, 2017 – BOSTON, MA, U.S.A. – Newborns are highly vulnerable to infections and don’t respond optimally to most vaccines because their young immune systems typically mount weak antibody responses. Now, researchers at Boston Children’s Hospital report achieving strong vaccine responses in newborn animals, including monkeys—the final preclinical model before human trials—by adding compounds known as adjuvants that boost the immune response. In two simultaneous papers, they also describe improved adjuvant formulations that could reduce side effects.

Read More

Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies

PRNewswire: March 22, 2017 – JERUSALEM, Israel – Intec Pharma Ltd. (Nasdaq; TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the initiation of a phase I clinical trial of AP-CBD/THC, its Accordion Pill platform with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed by Intec for various indications, including low back pain and fibromyalgia.

Read More

For more Company News, click here

© Copyright Controlled Release Society  | Contact Us - Report a Bad Link |
Admin Access